Loading clinical trials...
Loading clinical trials...
Double-Blind, Randomized, Placebo-controlled, Safety and Efficacy Trial of BHV-3500 (Zavegepant) Intranasal for the Acute Treatment of Migraine
Conditions
Interventions
Zavegepant
Placebo
Locations
94
United States
Medical Affiliated Research Center
Huntsville, Alabama, United States
Coastal Clinical Research, LLC, An AMR Co.
Mobile, Alabama, United States
MD First Research
Chandler, Arizona, United States
Tucson Neuroscience Research
Tucson, Arizona, United States
Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States
Axiom Research, LLC
Colton, California, United States
Start Date
October 27, 2020
Primary Completion Date
October 10, 2021
Completion Date
October 22, 2021
Last Updated
April 24, 2023
NCT06735833
NCT06241313
NCT07018713
NCT06641466
NCT04715685
NCT07476053
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions